Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia.

Research output: Contribution to journalArticle

Abstract

Chronic myelogenous leukemia is a myeloproliferative disorder representing 20%-30% of all leukemias. The disease is characterized by a cytogenetic abnormality called the Philadelphia chromosome. Except in patients who have undergone bone marrow transplantation (BMT), the natural history of chronic myelogenous leukemia has not changed in the last 30 years. Recombinant interferon alpha controls thrombocytosis and leukocytosis, reduces the leukemic infiltrate in the bone marrow, returns the spleen size to normal, and converts some patients to a normal chromosome pattern. This review summarizes the clinical and cytogenetic responses to date. The most significant observation is that, aside from treatment with BMT, interferon is the only agent that induces cytogenetic remissions.

Original languageEnglish (US)
Pages (from-to)8-11
Number of pages4
JournalOncology Nursing Forum
Volume16
Issue number6 Suppl
StatePublished - Nov 1989

Fingerprint

Biological Therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Interferon-alpha
Cytogenetics
Thrombocytosis
Philadelphia Chromosome
Myeloproliferative Disorders
Leukocytosis
Chromosome Aberrations
Interferons
Leukemia
Spleen
Chromosomes
Bone Marrow
Observation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Alpha interferon : progress and perspectives in the biotherapy of chronic myelogenous leukemia. / Habermann, Thomas Matthew.

In: Oncology Nursing Forum, Vol. 16, No. 6 Suppl, 11.1989, p. 8-11.

Research output: Contribution to journalArticle

@article{6ca09afebc8a435da2f8d717c9e83caf,
title = "Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia.",
abstract = "Chronic myelogenous leukemia is a myeloproliferative disorder representing 20{\%}-30{\%} of all leukemias. The disease is characterized by a cytogenetic abnormality called the Philadelphia chromosome. Except in patients who have undergone bone marrow transplantation (BMT), the natural history of chronic myelogenous leukemia has not changed in the last 30 years. Recombinant interferon alpha controls thrombocytosis and leukocytosis, reduces the leukemic infiltrate in the bone marrow, returns the spleen size to normal, and converts some patients to a normal chromosome pattern. This review summarizes the clinical and cytogenetic responses to date. The most significant observation is that, aside from treatment with BMT, interferon is the only agent that induces cytogenetic remissions.",
author = "Habermann, {Thomas Matthew}",
year = "1989",
month = "11",
language = "English (US)",
volume = "16",
pages = "8--11",
journal = "Oncology Nursing Forum",
issn = "0190-535X",
publisher = "Oncology Nursing Society",
number = "6 Suppl",

}

TY - JOUR

T1 - Alpha interferon

T2 - progress and perspectives in the biotherapy of chronic myelogenous leukemia.

AU - Habermann, Thomas Matthew

PY - 1989/11

Y1 - 1989/11

N2 - Chronic myelogenous leukemia is a myeloproliferative disorder representing 20%-30% of all leukemias. The disease is characterized by a cytogenetic abnormality called the Philadelphia chromosome. Except in patients who have undergone bone marrow transplantation (BMT), the natural history of chronic myelogenous leukemia has not changed in the last 30 years. Recombinant interferon alpha controls thrombocytosis and leukocytosis, reduces the leukemic infiltrate in the bone marrow, returns the spleen size to normal, and converts some patients to a normal chromosome pattern. This review summarizes the clinical and cytogenetic responses to date. The most significant observation is that, aside from treatment with BMT, interferon is the only agent that induces cytogenetic remissions.

AB - Chronic myelogenous leukemia is a myeloproliferative disorder representing 20%-30% of all leukemias. The disease is characterized by a cytogenetic abnormality called the Philadelphia chromosome. Except in patients who have undergone bone marrow transplantation (BMT), the natural history of chronic myelogenous leukemia has not changed in the last 30 years. Recombinant interferon alpha controls thrombocytosis and leukocytosis, reduces the leukemic infiltrate in the bone marrow, returns the spleen size to normal, and converts some patients to a normal chromosome pattern. This review summarizes the clinical and cytogenetic responses to date. The most significant observation is that, aside from treatment with BMT, interferon is the only agent that induces cytogenetic remissions.

UR - http://www.scopus.com/inward/record.url?scp=0024762003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024762003&partnerID=8YFLogxK

M3 - Article

C2 - 2687814

AN - SCOPUS:0024762003

VL - 16

SP - 8

EP - 11

JO - Oncology Nursing Forum

JF - Oncology Nursing Forum

SN - 0190-535X

IS - 6 Suppl

ER -